

THROUGH COURIER/FAX – 022-26598237, 26598238

FHL/SEC/S-2/AR/2010-11

November 2, 2010

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra – Kurla Complex,
Bandra (East),
Mumbai - 400051

**Sub: “Un-audited Financial Results” of the Company for the
Quarter ended 30th September, 2010**

Dear Sirs,

This is further to our Letter dated October 22, 2010, wherein it was informed that a Meeting of Board of Directors of the Company is scheduled to be held on 2nd November, 2010, to inter alia, take on record the Un-audited Financial Results of the Company, for the Quarter ended 30th September, 2010.

Accordingly, in terms of Clause 41 of the Listing Agreement, please find enclosed the “Un-Audited Financial Results” of the Company for the Quarter ended 30th September, 2010, which were approved by the Board of Directors of the Company at its Meeting held today, i.e., 2nd November, 2010.

A copy of the press release being issued in this regard is also enclosed.

This is for your information and records please.

Thanking you,

Yours faithfully,
For Fortis Healthcare Limited




Ruchi Mahajan
**Ruchi Mahajan
Company Secretary**

Encl: As above

FORTIS HEALTHCARE LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2010

Particulars	Consolidated						Standalone						Rs. In Lacs
	Quarter Ended Sep 30		Six Months ended Sep 30		Year Ended March 31	Quarter Ended Sep 30		Six Months ended Sep 30		Year Ended March 31			
	2010	2009	2010	2009	2010	2010	2009	2010	2009	2010			
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			
1. Income from Operations	35,473	18,758	68,898	37,036	92,675	6,255	4,764	12,188	9,623	20,117			
2. Other Operating Income	312	291	679	557	1,119	241	210	463	409	864			
3. Total Income	35,785	19,049	69,577	37,593	93,794	6,496	4,974	12,651	10,032	20,981			
4. Expenditure													
(a) Material Consumed	9,390	5,327	18,741	10,755	26,267	1,746	1,229	3,460	2,545	5,491			
(b) Employees cost	6,719	4,197	12,992	8,447	19,500	1,477	1,049	2,679	2,324	4,723			
(c) Net Depreciation & Amortization	2,329	1,176	4,481	2,311	5,994	274	261	541	518	1,079			
(d) Other expenditure	31,166	6,540	44,579	12,596	33,979	2,790	2,125	5,126	4,152	8,561			
(e) Total	49,604	17,240	80,793	34,109	85,740	6,287	4,664	11,806	9,539	19,854			
5. Profit (+)/ Loss (-) from Operations before Other income & Interest (3-4)	(13,819)	1,809	(11,216)	3,484	8,054	209	310	845	493	1,127			
6. Other Income	35,826	359	39,192	667	5,012	5,487	394	9,756	779	4,115			
7. Profit (+)/ Loss (-) from Operations before Interest (5-6)	22,007	2,168	27,976	4,151	13,066	5,696	704	10,601	1,272	5,242			
8. Interest (including finance charges)	13,525	776	20,818	1,817	5,729	1,934	484	4,076	1,200	2,228			
9. Profit (+)/ Loss (-) from Ordinary activists before tax (7-8)	8,482	1,392	7,358	2,334	7,337	3,762	220	6,525	72	3,014			
10. Tax expense	303	93	520	275	336	-	(8)	-	-	-			
11. Net Profit/ Loss (9-10)	8,179	1,299	6,838	2,059	7,001	3,762	228	6,525	72	3,014			
12. Less : Minority Interest in profit / (loss)	(41)	83	60	141	209	-	-	-	-	-			
13. Add : Share in profit/(loss) of associate companies	(742)	81	(731)	134	156	-	-	-	-	-			
14. Net Profit / (Loss) attributable to the shareholders of the Company	7,478	1,297	6,047	2,052	6,948	3,762	228	6,525	72	3,014			
15. Paid-up equity share capital (Face Value Rs.10 per Share)	40,506	22,667	40,506	22,667	31,732	40,506	22,667	40,506	22,667	31,732			
16. Reserves excluding Revaluation Reserves					119,150					137,363			
17.Earnings Per Share :- Basic	2.05	0.57	1.66	0.91	2.62	1.03	0.10	1.79	0.03	1.14			


 Anurag Kumar
 Certified True Copy
 For Fortis Healthcare India Pvt. Ltd.
 Company Secretary

19. Promoters and promoter group Shareholding									
a) Pledged/ Encumbered - No of Shares	127,190,500	39,340,500	127,190,500	39,340,500	127,190,500	39,340,500	127,190,500	39,340,500	164,817,692
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	38.5%	25.4%	38.5%	25.4%	38.5%	25.4%	38.5%	25.4%	67.9%
- Percentage of shares (as a % of the total share capital of the company)	31.4%	17.4%	31.4%	17.4%	31.4%	17.4%	31.4%	17.4%	51.9%
b) Non-encumbered - No of Shares	202,963,449	115,823,741	202,963,449	115,823,741	202,963,449	115,823,741	202,963,449	115,823,741	77,830,953
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	61.5%	74.6%	61.5%	74.6%	61.5%	74.6%	61.5%	74.6%	32.1%
- Percentage of shares (as a % of the total share capital of the company)	50.1%	51.1%	50.1%	51.1%	50.1%	51.1%	50.1%	51.1%	24.5%

Notes:

1. The financial results for the quarter ended September 30, 2010 have been reviewed by the Audit, Risk & Controls Committee and approved by the Board of Directors at their respective meetings held on November 2, 2010. The financial results have been subjected to the limited review by the Statutory Auditors in terms of Clause 41 of Listing Agreement.
2. The Group is primarily engaged in the business of healthcare services, which as per Accounting Standard 17 on 'Segment Reporting' issued by the ICAI is considered to be the only reportable business segment. The Group's operating locations are based in India which is considered as a single geographical segment.
3. Other income includes interest income, unclaimed balances and excess provisions written back, foreign exchange fluctuation gain, profit on sale of assets, profit on sale of investment, claim received against key man insurance policy and miscellaneous income, whichever is relevant for the period/year.
4. The statutory auditors have reported in the auditor's report on consolidated financial statements for the year ended March 31, 2010 about their inability to express an opinion on the matter relating to land under leasehold arrangements with the Delhi Development Authority and certain demands raised by the income tax authorities in respect of a subsidiary aggregating to Rs. 9,608 lacs. As the matters are sub-judice, and appeals against the demands are pending at various stages and based on the advice received from legal counsels, the management is of the view that the matters shall get resolved in its favor.
5. The funds raised through Initial Public Offer in April 2007 have been fully utilized in June 2010. The status of fund utilization out of Rights Issue Proceeds as at the end of September 30, 2010 is as follows:

S no.	Expenditure Program	(Rs. in lacs)	
		Amount expended till September 30, 2010	
1	Investment in wholly owned subsidiary (Fortis Hospitel Limited) to finance the construction and development of a Greenfield hospital project in Gurgaon, Haryana		20,000
2	Acquisitions and other strategic initiatives		20,000
3	Redemption of Preference Shares (Class C), along with the premium on such redemption		26,000
4	Repayment and prepayment of existing short term loans of the Company		17,100
5	General corporate purpose		15,312
6	Issue expenses		1,300
	Total		99,712

The Company has utilized entire amount of Rs. 99,712 lacs raised from the Rights Issue.



amur siddhar

6. Statement of Assets & Liabilities of the Company

Particulars	(Rs. In lacs)			
	Consolidated		Standalone	
	September 30, 2010 (Unaudited)	September 30, 2009* (Unaudited)	September 30, 2010 (Unaudited)	September 30, 2009* (Unaudited)
SOURCES OF FUNDS				
Share Capital	40,939	23,125	40,939	23,125
Share Application Money Pending Allotment	-	42,006	-	42,006
Reserves & Surplus	295,843	112,151	259,480	74,694
Minority Interest	3,510	2,295	-	-
Secured Loans	56,240	20,971	3,730	10,447
Unsecured Loans	85,178	4,260	73,877	4,000
TOTAL	481,710	204,808	378,026	154,272
APPLICATION OF FUNDS				
Goodwill arising on Consolidation	41,638	39,606	-	-
Goodwill on acquisition	44,624	-	-	-
Fixed Assets (including CWIP)	175,198	106,668	7,551	7,348
Investments	109,215	21,461	239,455	80,114
Deferred Tax Assets (Net)	1,240	245	-	-
Net Current Assets	96,608	14,044	126,238	52,540
Miscellaneous Expenditure	99	40	21	40
(to the extent not written off or adjusted)				
Profit and Loss Account	13,088	22,744	4,761	14,230
TOTAL	481,710	204,808	378,026	154,272

* Amounts pertaining to September 30, 2009 have not been audited or reviewed by the auditors.

7. During the quarter, the Company through one of its subsidiary, Fortis Global Healthcare (Mauritius) Limited has sold its entire stake of 24.88% in Parkways Holdings Limited at the price of SG\$ 3.95 per share to the Integrated Healthcare Holdings Limited, resulting in sale consideration of Rs. 383,981 lacs and gain on the sale of this investment and related transactions amounting to Rs 34,262 lacs has been reported under Other Income. Further, the other expenditure for the quarter includes Rs.17,430 lacs incurred for legal and professional charges, structuring fee paid to the merchant bankers & lawyers and exchange loss etc. related to the Parkway transaction.
8. During the quarter, the Company has commissioned two new tertiary care hospitals deepening its presence in the two Metros viz. a multidisciplinary tertiary care 350 bedded hospital at Shalimar Bagh, New Delhi and a 414 bedded Hospital, at Anandapura, Kolkata. In addition, Fortis Hospitals Mulund inaugurated its state-of-the-art Oncology Block and with this, the hospital is full equipped to provide holistic Cancer Care including Radiation therapy.
9. Number of Investors Complaints received and disposed off during the quarter ended September 30, 2010: (i) Pending at the beginning of the quarter – Nil. (ii) Received during



amrinder


the quarter – Nil. (iii) Disposed of during the quarter – Nil (iv) Lying unresolved at the end of the quarter – Nil.

10. On August 6, 2010, the Company has allotted 4,600 Equity Shares of Rs. 10/- each, out of which 4,000 shares have been allotted at a premium of Rs. 61/- per share and 600 shares have been allotted at a premium of Rs. 67/- per share, to the eligible employees, upon exercise of vested stock options, under the 'Employee Stock Option Plan 2007' of the Company. Accordingly, the Paid up equity share capital of the Company has been increased from Rs. 40,505.72 lacs to Rs.40,506.18 lacs.

11. The Previous Periods figures have been regrouped and recasted, wherever considered necessary.

Date: November 02, 2010
Place: Gurgaon

for and on behalf of the Board of Directors



Shivinder Mohan Singh
Managing Director


17.02.25

Regd. Office: Escorts Heart Institute & Research Centre, Okhla Road, New Delhi – 110 025

Certified True Copy

For Board of Directors


General Secretary

PRESS RELEASE

FORTIS HEALTHCARE Q2 REVENUE UP 88 % TO ₹ 358 CRORE

OPERATING EBITDA AT ₹ 50 CR, UP 67%

NET PROFIT UP 477% TO ₹ 75 CRORE


Gurgaon, November 02, 2010: Fortis Healthcare Limited, one of India's leading healthcare service providers with a network of 49 hospitals and a capacity of ~ 8000 beds, today announced its unaudited consolidated results for the quarter ended September 30, 2010.

During the quarter the Company commissioned two new tertiary care hospitals, strengthening its presence in two Metros. It's first Greenfield in the capital city, a Multidisciplinary tertiary care 350 bed hospital at Shalimar Bagh, New Delhi launched its services in September and a 414 bed Hospital, at Anandpur, Kolkata also commenced OPD and IPD services in September '10.

In addition, Fortis Hospitals' Mulund facility inaugurated its state-of-the-art Oncology Block, equipped with high-end Linear accelerator with IMRT, IGRT and SRS in September, which now provides holistic care including Medical, Surgical and Radiation therapy to cancer patients. Furthermore, the Company continued to establish new benchmarks in the healthcare sector by delivering an array of cutting-edge procedures and advanced therapy at its network of hospitals.

Financial Highlights


- **Net profit for the quarter stood at ₹ 74.8 Cr, a growth of 477% compared to the corresponding quarter of the previous year. This includes the net profit of ₹ 53.9 Cr made on the divesture of Parkway investments.**
- The Company continued its growth momentum during the quarter and the consolidated operating revenues were at ₹ 357.8 Cr, a growth of 88%, compared to the corresponding period last fiscal. This was led by impressive performance by Fortis Noida, Fortis Mohali, Fortis Malar and Fortis Jaipur Hospitals which grew by 50%, 37%, 37% and 34% respectively.
- The EBITDA from base operations grew to ₹ 49.9 Cr (13.9% of Revenue), up 67% over Q2FY'10.
- For the half year ended September 30, 2010, the operating revenue grew by 85% to ₹ 695.7 Cr. The growth has been led primarily by Fortis Noida, Fortis Mohali, Fortis Malar and Fortis Jaipur Hospitals which grew by 45%, 31%, 35% and 35% respectively.

Certified True Copy
For Fortis Healthcare Ltd.

Company Secretary

- EBIDTA from base operations increased by 70% to ₹ 98.5 Cr (14.2% of Revenue) in H1FY'11.
- During the same period, net profit has grown by 195% to ₹ 60.5 Cr.

Operational Highlights:

- The Company expanded its footprint into Eastern India with the commissioning of its 414 bed Hospital at Anandpur, Kolkata. This facility will provide a super-speciality care in the fields of Cardiac Sciences, Gastroenterology and related sciences, Orthopaedics, Neurosciences and Oncology.
- With the launch of its seventh operating facility in the NCR, a 350 bed hospital at Shalimar Bagh, North-West Delhi, the Company bolstered its pre-eminent position in the NCR region. The compassionate care at the hospital has been well received by the local populace and the occupancies ramped up to 80% of operational beds within a few days of launch.
- A new Oncology block with a capacity of 110 beds was commissioned at the Fortis Mulund Hospital, Mumbai and offers holistic cancer care including radiation therapy. Post the ongoing planned expansion, the hospital will have a capacity of 500 beds.
- The Company made its foray into Africa and UAE during the quarter. A Heart Command Centre was set up Medical Centre (RMC) in Tanzania, Africa by the Fortis Escorts Heart Institute (FEHI), Delhi. In Dubai, UAE, Fortis will set up a paediatric interventional cardiac unit at RAK Hospital. This will establish Fortis' presence in a region that is home to many patients, who place their trust in Fortis and travel to India for treatment.
- The Company also started the construction work at its 200 bed Multi-disciplinary tertiary care hospital in Ludhiana. The hospital will be operational in FY12 and would offer services in the area of Cardiac sciences, Oncology, Orthopaedics and Neurosciences.
- In order to further the development of advanced methods of tertiary care in the area of Cardiac sciences, FEHI, Delhi obtained regulatory approval to participate in the clinical trials of new coronary artery stents that get absorbed by the body. The hospital thus joined an elite list of 100 institutions worldwide, participating in this unique study that has the potential to revolutionize the management of coronary artery disease.
- Post the launch of the Voluntary General Offer (VGO) by Khazanah at S \$ 3.95 per share, the Company withdrew its VGO and tendered its entire stake. The Company received the proceeds of the tendered shares on August 20, 2010 which have been applied to pay off the debts raised for acquisition of the Parkway stake.



Commenting on the results, Mr. Shivinder M Singh, Managing Director, Fortis Healthcare Limited, said, "The last quarter has been very exciting for us with increasing footholds in both Indian and overseas markets. We remain committed to medical excellence and world-class quality as we build on the recognition Fortis enjoys, as a trusted name in healthcare. Our enhanced medical capability is demonstrated by the large numbers of cutting-edge procedures performed by our talented doctors; and Fortis' newly expanded capacity in the key metros of Delhi, Kolkata and Mumbai will help us touch more lives."


Network hospitals:

All the Network hospitals reported robust growth in the revenues and profitability during the quarter. The Network revenues stood at ₹ 442 Cr, a growth of 66% as compared to Q2 FY 2010. The Network continues to witness a healthy growth in International Patient revenue, which grew to three times over the corresponding quarter last year and 17% over the trailing quarter to ₹ 24.5 Cr.

Over 12,000 cardiac procedures were performed that included 2,552 Angioplasties and 2,330 CTVS procedures. Additionally, a total of 1,432 joint replacements and 58 Renal Transplants were carried out across the network hospitals.

Income from key Super Specialities such as Cardiac sciences, Orthopaedics and Neurosciences grew by 43%, 53% and 117% respectively, across the network. Similarly, revenues from Renal Sciences, Pulmonology and Gastroenterology grew by 28%, 56% and 36%; respectively. Occupancies and revenues in the network hospitals, especially the Northern India, witnessed higher growth due to outburst of dengue in the region.

The Company continues to carry out unprecedented procedures with its dedicated team of clinicians, using novel techniques and setting new benchmarks in the delivery of high-end tertiary care.



About Fortis Healthcare Limited

Fortis Healthcare Limited is committed to clinical excellence and patient-centric healthcare, which is manifest in hospital design, patient services, medical programmes and the compassionate approach of medical and non-medical hospital staff. Fortis commissioned its first hospital in 2001 at Mohali, near Chandigarh, and has expanded its operations to become a network with around 8000 bed capacity across 49 hospitals. The Fortis network has a large number of international accreditations, including four JCI (Joint Commission International) and six NABH (National Accreditation Board for Hospitals) certifications. The network's capability covers multi-speciality hospitals and super-speciality centres that provide tertiary and quaternary healthcare to patients in the major medical specialities.

DISCLAIMER


This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

For further details please contact:

Ranjana Smetacek / Ruhee Dhar
Fortis Healthcare Ltd
9958999840 / 9818102377

Gaurav Chugh / Pawanpreet Singh
Fortis Healthcare Limited
9958588900

Hiren Shah/Sahana Chowdhury
Hanmer MSL Mumbai
9820384223 / 9892826469

Certified True Copy
Per Fortis Healthcare Ltd

Managing Secretary